Fierce Biotech News & Reports

Why Valneva CEO remains bullish on Pfizer-partnered Lyme vaccine

Despite a phase 3 miss and a difficult regulatory environment, Valneva and Pfizer remain hopeful about scoring an approval for their Lyme disease shot.

Angus Liu Apr 1, 2026 3:00pm

Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials

Apr 2, 2026 7:27am

Scaling Radioligand Therapy: Expanding the Impact of Theranostics

Brought to you by Curium

Alto halts work on PDE4 inhibitor after ph. 2 schizophrenia fail

Apr 2, 2026 7:17am

Gilead cancels HIV trial as clinical hold remains intact

Apr 1, 2026 4:50pm

Charming view of the seaside resort town of Kas in Turkey Romantic lighthouse at the entrance to the port and a paraglider f

Bayer radiology head takes top U.S. pharma spot—Chutes & Ladders

Apr 3, 2026 8:30am

More News

Fierce Pharma

UK government agrees to pharma deal, ensuring tariff reprieve

Apr 2, 2026 3:34pm

Ferring terminates fertility trials after ‘portfolio assessment’

Apr 2, 2026 2:00pm

Epia launches to help stroke patients rework brain signals

Apr 2, 2026 10:00am

Drug combo treats cancers with ‘paradox’ mutation in mice

Apr 1, 2026 2:00pm

See more stories